194 related articles for article (PubMed ID: 22038541)
1. The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Matok I; Levy A; Wiznitzer A; Uziel E; Koren G; Gorodischer R
Dig Dis Sci; 2012 Mar; 57(3):699-705. PubMed ID: 22038541
[TBL] [Abstract][Full Text] [Related]
2. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy.
Daniel S; Matok I; Gorodischer R; Koren G; Uziel E; Wiznitzer A; Levy A
J Rheumatol; 2012 Nov; 39(11):2163-9. PubMed ID: 22984274
[TBL] [Abstract][Full Text] [Related]
3. The safety of H(2)-blockers use during pregnancy.
Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Uziel E; Levy A
J Clin Pharmacol; 2010 Jan; 50(1):81-7. PubMed ID: 19789371
[TBL] [Abstract][Full Text] [Related]
4. Fetal safety of macrolides.
Bahat Dinur A; Koren G; Matok I; Wiznitzer A; Uziel E; Gorodischer R; Levy A
Antimicrob Agents Chemother; 2013 Jul; 57(7):3307-11. PubMed ID: 23650169
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
[TBL] [Abstract][Full Text] [Related]
6. The safety of metoclopramide use in the first trimester of pregnancy.
Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Levy A
N Engl J Med; 2009 Jun; 360(24):2528-35. PubMed ID: 19516033
[TBL] [Abstract][Full Text] [Related]
7. Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations.
Goldberg O; Koren G; Landau D; Lunenfeld E; Matok I; Levy A
J Clin Pharmacol; 2013 Sep; 53(9):991-5. PubMed ID: 23873250
[TBL] [Abstract][Full Text] [Related]
8. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists.
Levy A; Matok I; Gorodischer R; Sherf M; Wiznitzer A; Uziel E; Koren G
J Clin Pharmacol; 2012 Jan; 52(1):78-83. PubMed ID: 21343345
[TBL] [Abstract][Full Text] [Related]
9. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study.
Rotem R; Fishman B; Daniel S; Koren G; Lunenfeld E; Levy A
BJOG; 2018 Nov; 125(12):1550-1556. PubMed ID: 29790255
[TBL] [Abstract][Full Text] [Related]
10. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations.
Matok I; Gorodischer R; Koren G; Landau D; Wiznitzer A; Levy A
Br J Clin Pharmacol; 2009 Dec; 68(6):956-62. PubMed ID: 20002091
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.
Nikfar S; Abdollahi M; Moretti ME; Magee LA; Koren G
Dig Dis Sci; 2002 Jul; 47(7):1526-9. PubMed ID: 12141812
[TBL] [Abstract][Full Text] [Related]
12. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.
Gill SK; O'Brien L; Einarson TR; Koren G
Am J Gastroenterol; 2009 Jun; 104(6):1541-5; quiz 1540, 1546. PubMed ID: 19491869
[TBL] [Abstract][Full Text] [Related]
13. Teratogenic determinants of first-trimester exposure to antiepileptic medications.
Brosh K; Matok I; Sheiner E; Koren G; Wiznitzer A; Gorodischer R; Levy A
J Popul Ther Clin Pharmacol; 2011; 18():e89-98. PubMed ID: 21467600
[TBL] [Abstract][Full Text] [Related]
14. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations.
Choi A; Noh Y; Jeong HE; Choi EY; Man KKC; Han JY; Kim HS; Yon DK; Shin JY
JAMA Netw Open; 2023 Jan; 6(1):e2250366. PubMed ID: 36626173
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcome following opioid exposure: A cohort study.
Fishman B; Daniel S; Koren G; Lunenfeld E; Levy A
PLoS One; 2019; 14(7):e0219061. PubMed ID: 31260464
[TBL] [Abstract][Full Text] [Related]
16. The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy.
Daniel S; Doron M; Fishman B; Koren G; Lunenfeld E; Levy A
Br J Clin Pharmacol; 2019 Dec; 85(12):2856-2863. PubMed ID: 31486528
[TBL] [Abstract][Full Text] [Related]
17. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.
Graner S; Svensson T; Beau AB; Damase-Michel C; Engeland A; Furu K; Hviid A; Håberg SE; Mølgaard-Nielsen D; Pasternak B; Kieler H
BMJ; 2017 Feb; 356():j629. PubMed ID: 28246106
[No Abstract] [Full Text] [Related]
18. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Diav-Citrin O; Arnon J; Shechtman S; Schaefer C; van Tonningen MR; Clementi M; De Santis M; Robert-Gnansia E; Valti E; Malm H; Ornoy A
Aliment Pharmacol Ther; 2005 Feb; 21(3):269-75. PubMed ID: 15691301
[TBL] [Abstract][Full Text] [Related]
19. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
20. Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy.
Källén BA
Eur J Obstet Gynecol Reprod Biol; 2001 May; 96(1):63-8. PubMed ID: 11311763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
